Latest news and press releases about Sutro Biopharma, Inc. (STRO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
Price
| Price | $15.60 |
| Market Cap | $151M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -2.10 |
| EV / EBITDA | -0.89 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 185.30% |
| Return on Invested Capital | -95.49% |
| Return on Assets | -92.89% |
| Gross Margin | 97.20% |
| Operating Margin | -309.87% |
| Net Margin | -395.25% |
Related companies: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explore sector: Healthcare · Biotechnology
More sections of STRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks